ArticleOncology letters2025
Rare diagnosis of locally advanced triple‑negative breast cancer with paraneoplastic dermatomyositis: A case report and literature review.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Dermatomyositis as a paraneoplastic sign of breast cancer: a case report and literature review.International journal of surgery case reports · 2026Article
- Case Report: breast cancer presenting as dermatomyositis.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Paraneoplastic dermatomyositis (DM) is a rare autoimmune condition that primarily affects the skin and muscles; it is associated with various malignancies, including breast cancer. The present case report investigates the clinical presentation, therapeutic considerations and relevant literature regarding DM in the context of locally advanced triple-negative breast cancer (TNBC). A 43-year-old female patient presented with progressive myalgia, dysphagia and characteristic skin rashes. Subsequent investigations confirmed locally advanced TNBC and concomitant DM. Due to the severely weakened state of the patient, the standard treatment of neoadjuvant chemotherapy was contraindicated. The patient initially received corticosteroid therapy, which led to partial symptom improvement, followed by a modified radical mastectomy and adjuvant chemotherapy. Following surgical intervention, the patient experienced significant alleviation of DM symptoms. The present study underscores the critical role of early malignancy identification and intervention in managing DM associated with breast cancer; in addition, it explores the epidemiology, risk factors, pathogenesis, diagnostic modalities and treatment strategies for breast cancer-associated DM. The potential challenges in treatment selection are highlighted, particularly in patients with severe presentations. Mastectomy can emerge as a viable therapeutic option to achieve symptom control and facilitate subsequent oncological management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.